These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 7936114

  • 1. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
    Fang J, Yu PH.
    Neuropharmacology; 1994 Jun; 33(6):763-8. PubMed ID: 7936114
    [Abstract] [Full Text] [Related]

  • 2. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 3. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP, Lamensdorf I, Armoni T.
    Neurobiology (Bp); 2000 Jun 29; 8(2):137-42. PubMed ID: 11061211
    [Abstract] [Full Text] [Related]

  • 4. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct 29; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 5. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
    Ilani T, Lamensdorf I, Finberg JP.
    Br J Pharmacol; 2000 Aug 29; 130(8):1992-8. PubMed ID: 10952692
    [Abstract] [Full Text] [Related]

  • 6. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J, Takahashi T, Agata M, Toyofuku H, Sasada N.
    Jpn J Pharmacol; 1994 May 29; 65(1):51-7. PubMed ID: 8089930
    [Abstract] [Full Text] [Related]

  • 7. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
    Tekes K, Tóthfalusi L, Gaál J, Magyar K.
    Pol J Pharmacol Pharm; 1988 May 29; 40(6):653-8. PubMed ID: 3152003
    [Abstract] [Full Text] [Related]

  • 8. L-deprenyl (selegiline) limits the repetitive firing of action potentials in rat hippocampal CA1 neurons via a dopaminergic mechanism.
    Huang CC, Tsai JJ, Hsu KS.
    Brain Res; 1997 Apr 04; 753(1):27-35. PubMed ID: 9125428
    [Abstract] [Full Text] [Related]

  • 9. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J, Miklya I.
    Arch Int Pharmacodyn Ther; 1994 Apr 04; 328(1):1-15. PubMed ID: 7893186
    [Abstract] [Full Text] [Related]

  • 10. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F.
    Br J Pharmacol; 1987 Feb 04; 90(2):335-45. PubMed ID: 3103805
    [Abstract] [Full Text] [Related]

  • 11. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K.
    J Pharmacol Exp Ther; 1987 Jan 04; 240(1):251-8. PubMed ID: 3100771
    [Abstract] [Full Text] [Related]

  • 12. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.
    J Neural Transm (Vienna); 2001 Jan 04; 108(8-9):985-1009. PubMed ID: 11716151
    [Abstract] [Full Text] [Related]

  • 13. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW, Hemrick-Luecke SK, Kindt MV, Heikkila RE.
    Life Sci; 1988 Jan 04; 42(3):263-71. PubMed ID: 3121972
    [Abstract] [Full Text] [Related]

  • 14. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
    Tekes K, Magyar K.
    Neurobiology (Bp); 2000 Jan 04; 8(3-4):257-64. PubMed ID: 11225517
    [Abstract] [Full Text] [Related]

  • 15. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR, Abercrombie ED.
    J Neurochem; 1994 Jul 04; 63(1):108-17. PubMed ID: 8207420
    [Abstract] [Full Text] [Related]

  • 16. Thyroid iodide transport is reduced by administration of monoamine oxidase A inhibitors to rats.
    Cabanillas AM, Masini-Repiso AM, Costamagna ME, Pellizas C, Coleoni AH.
    J Endocrinol; 1994 Nov 04; 143(2):303-8. PubMed ID: 7829993
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
    Paterson IA, Juorio AV, Berry MD, Zhu MY.
    J Pharmacol Exp Ther; 1991 Sep 04; 258(3):1019-26. PubMed ID: 1679846
    [Abstract] [Full Text] [Related]

  • 18. Involvement of Ca2+ in dopamine release in striatal rat slices by PF9601N and L-deprenyl.
    Pérez V, Pastó M, Unzeta M.
    Neurobiology (Bp); 2000 Sep 04; 8(3-4):237-42. PubMed ID: 11225514
    [Abstract] [Full Text] [Related]

  • 19. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J.
    Vopr Med Khim; 1997 Sep 04; 43(6):482-93. PubMed ID: 9503565
    [Abstract] [Full Text] [Related]

  • 20. Monoamine oxidase inhibitor-induced blockade of locomotor sensitization to quinpirole: role of striatal dopamine uptake inhibition.
    Culver KE, Rosenfeld JM, Szechtman H.
    Neuropharmacology; 2002 Sep 04; 43(3):385-93. PubMed ID: 12243768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.